XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q2)Jan 31, 2025 | (Q1)Oct 31, 2024 | (FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | (Q2)Jan 31, 2024 | (Q1)Oct 31, 2023 | (FY)Jul 31, 2023 | (Q4)Jul 31, 2023 | (Q3)Apr 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.29%2.26B | 13.88%2.14B | 16.46%8.03B | 12.09%2.19B | 15.33%1.98B | 19.33%1.98B | 20.13%1.88B | 25.29%6.89B | 25.98%1.95B | 24.10%1.72B |
Operating revenue | 14.29%2.26B | 13.88%2.14B | 16.46%8.03B | 12.09%2.19B | 15.33%1.98B | 19.33%1.98B | 20.13%1.88B | 25.29%6.89B | 25.98%1.95B | 24.10%1.72B |
Cost of revenue | 20.06%599.2M | 17.20%554.1M | 7.83%2.06B | 13.20%573.7M | 8.17%513.6M | 7.06%499.1M | 2.36%472.8M | 11.11%1.91B | 2.95%506.8M | 7.79%474.8M |
Gross profit | 12.34%1.66B | 12.77%1.58B | 19.77%5.97B | 11.70%1.62B | 18.06%1.47B | 24.15%1.48B | 27.58%1.41B | 31.73%4.98B | 36.69%1.45B | 31.70%1.25B |
Operating expense | -0.32%1.42B | 9.08%1.3B | 14.99%5.28B | 15.46%1.38B | 10.89%1.29B | 23.79%1.42B | 9.56%1.19B | 15.71%4.6B | 14.40%1.19B | 17.47%1.17B |
Selling and administrative expenses | -6.40%912.1M | 4.77%817.8M | 16.15%3.48B | 13.36%882.6M | 11.09%837.3M | 30.82%974.5M | 9.25%780.6M | 17.14%2.99B | 14.67%778.6M | 18.06%753.7M |
-Selling and marketing expense | 12.67%758.3M | 9.02%720.1M | 9.85%2.79B | 11.79%742.3M | 12.38%718.7M | 7.59%673M | 7.40%660.5M | 18.39%2.54B | 16.37%664M | 17.64%639.5M |
-General and administrative expense | -48.99%153.8M | -18.65%97.7M | 52.00%680.5M | 22.43%140.3M | 3.85%118.6M | 152.51%301.5M | 20.70%120.1M | 10.54%447.7M | 5.72%114.6M | 20.46%114.2M |
Research and development costs | 12.90%505.7M | 17.31%480.4M | 12.81%1.81B | 19.40%494.8M | 10.51%457.2M | 10.84%447.9M | 10.14%409.5M | 13.14%1.6B | 13.91%414.4M | 16.40%413.7M |
Operating profit | 348.51%240.4M | 33.13%286.5M | 76.58%683.9M | -5.96%238.4M | 124.52%176.7M | 34.34%53.6M | 1,315.79%215.2M | 305.14%387.3M | 1,546.10%253.5M | 265.34%78.7M |
Net non-operating interest income expense | -101.09%-900K | 23.72%84.5M | 57.00%309.6M | 23.95%82.8M | 30.81%76M | 66.00%82.5M | 202.21%68.3M | 1,771.19%197.2M | 2,285.71%66.8M | 1,483.33%58.1M |
Non-operating interest income | ---- | 20.37%85.7M | 41.67%317.9M | 14.62%83.1M | 18.82%78.3M | 50.71%85.3M | 142.18%71.2M | 1,338.46%224.4M | 647.42%72.5M | 2,434.62%65.9M |
Non-operating interest expense | -47.06%900K | -63.16%700K | -76.59%4.8M | -220.00%-3.2M | -70.51%2.3M | -67.31%1.7M | -62.00%1.9M | 1.49%20.5M | -233.33%-1M | 14.71%7.8M |
Total other finance cost | ---- | -50.00%500K | -47.76%3.5M | ---- | ---- | -35.29%1.1M | -44.44%1M | -6.94%6.7M | ---- | ---- |
Other net income (expense) | 14,316.67%85.3M | -166.67%-2.4M | 71.43%-5.2M | 42.11%-2.2M | 74.14%-1.5M | 88.46%-600K | 73.53%-900K | -175.76%-18.2M | -322.22%-3.8M | -728.57%-5.8M |
Gain on sale of security | ---- | -247.06%-7.5M | 102.53%200K | 3.57%-2.7M | 295.45%4.3M | 10.96%-6.5M | 15.91%5.1M | -538.89%-7.9M | -171.79%-2.8M | -162.86%-2.2M |
Other non- operating income (expenses) | 1,345.76%85.3M | 185.00%5.1M | 47.57%-5.4M | 150.00%500K | -61.11%-5.8M | 180.95%5.9M | 23.08%-6M | -22.62%-10.3M | 79.17%-1M | 14.29%-3.6M |
Income before tax | 139.70%324.8M | 30.43%368.6M | 74.52%988.3M | 0.79%319M | 91.76%251.2M | 60.55%135.5M | 721.51%282.6M | 373.31%566.3M | 1,729.48%316.5M | 349.52%131M |
Income tax | 103.57%57.5M | -79.75%17.9M | -1,355.37%-1.59B | -143.58%-38.7M | -218.97%-27.6M | -805,800.00%-1.61B | 513.89%88.4M | 111.71%126.6M | 534.29%88.8M | 12.08%23.2M |
Net income | -84.70%267.3M | 80.59%350.7M | 486.22%2.58B | 57.09%357.7M | 158.63%278.8M | 1,974.70%1.75B | 871.00%194.2M | 264.68%439.7M | 6,800.00%227.7M | 247.27%107.8M |
Net income continuous Operations | -84.70%267.3M | 80.59%350.7M | 486.22%2.58B | 57.09%357.7M | 158.63%278.8M | 1,974.70%1.75B | 871.00%194.2M | 264.68%439.7M | 6,800.00%227.7M | 247.27%107.8M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -84.70%267.3M | 80.59%350.7M | 486.22%2.58B | 57.09%357.7M | 158.63%278.8M | 1,974.70%1.75B | 871.00%194.2M | 264.68%439.7M | 6,800.00%227.7M | 247.27%107.8M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -84.70%267.3M | 80.59%350.7M | 486.22%2.58B | 57.09%357.7M | 158.63%278.8M | 1,974.70%1.75B | 871.00%194.2M | 264.68%439.7M | 6,800.00%227.7M | 247.27%107.8M |
Basic earnings per share | -85.01%0.41 | 69.84%0.535 | 456.55%4.035 | 48.65%0.55 | 145.71%0.43 | 1,853.57%2.735 | 800.00%0.315 | 261.11%0.725 | 7,300.00%0.37 | 240.00%0.175 |
Diluted earnings per share | -84.46%0.38 | 76.79%0.495 | 468.75%3.64 | 57.81%0.505 | 154.84%0.395 | 1,856.00%2.445 | 833.33%0.28 | 242.22%0.64 | 6,300.00%0.32 | 224.00%0.155 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |